Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen

Архивировано 04.10.2021: via.ritzau.dk-2020-05-29-ebola.pdf

Источник: https://via.ritzau.dk/pressemeddelelse/nj-janssen?publisherId=90456&releaseId=13594271

Johnson & Johnson today announced that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species. Two Marketing Authorisation Applications (MAAs) were submitted to the EMA in support of the vaccines in the two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo).